Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 10 INDUSTRY 2 UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Platinum-resistant Recurrent Ovarian Cancer 1

Interventions

Capecitabine 15 Paclitaxel 13 S 1 (combination) 9 apatinib 8 Oxaliplatin 8 Carboplatin 8 Cisplatin 7 pyrotinib 6 Epirubicin 6 Docetaxel 6 sintilimab 5 camrelizumab 5 anlotinib 5 Radiotherapy 5 Drug Therapy 5 130-nm albumin-bound paclitaxel 5 nimotuzumab 4 nedaplatin 4 Vinorelbine 4 Temozolomide 4 Irinotecan 4 Fulvestrant 4 Etoposide 4 Bevacizumab 4 toripalimab 3 titanium silicide 3 exemestane 3 Trastuzumab 3 Radiotherapy, Intensity-Modulated 3 Radiosurgery 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × UNKNOWN × 1-dodecylpyridoxal × Clear all

NCT04348032 2022-03-31

APPROVE

ChineseAMS

Phase 2 Unknown

Platinum-resistant Recurrent Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡